Essex Investment Management Co. LLC Acquires 35,012 Shares of MediWound Ltd. (NASDAQ:MDWD)

Essex Investment Management Co. LLC raised its holdings in MediWound Ltd. (NASDAQ:MDWD) by 30.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,949 shares of the biopharmaceutical company’s stock after purchasing an additional 35,012 shares during the quarter. Essex Investment Management Co. LLC owned 1.38% of MediWound worth $2,651,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in MDWD. Yelin Lapidot Holdings Management Ltd. raised its position in MediWound by 13.4% in the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock worth $15,154,000 after acquiring an additional 100,618 shares during the period. Rhumbline Advisers raised its holdings in shares of MediWound by 7.3% in the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock worth $193,000 after purchasing an additional 739 shares during the period. Legato Capital Management LLC raised its holdings in shares of MediWound by 12.0% in the 4th quarter. Legato Capital Management LLC now owns 43,753 shares of the biopharmaceutical company’s stock worth $779,000 after purchasing an additional 4,681 shares during the period. Sargent Investment Group LLC lifted its stake in MediWound by 3.4% in the fourth quarter. Sargent Investment Group LLC now owns 121,190 shares of the biopharmaceutical company’s stock valued at $2,217,000 after purchasing an additional 3,998 shares during the last quarter. Finally, R Squared Ltd bought a new position in MediWound during the fourth quarter valued at $32,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Price Performance

NASDAQ:MDWD opened at $16.93 on Monday. The company has a market cap of $182.61 million, a P/E ratio of -5.84 and a beta of 0.82. MediWound Ltd. has a 1 year low of $12.78 and a 1 year high of $24.00. The stock’s fifty day moving average price is $18.06 and its two-hundred day moving average price is $17.63.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on MDWD. Craig Hallum assumed coverage on MediWound in a research report on Friday, February 28th. They set a “buy” rating and a $39.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of MediWound in a report on Friday, January 10th.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.